NCT02263131View on ClinicalTrials.gov

Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children

PHASE3CompletedINTERVENTIONAL
Enrollment

416

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

June 30, 2014

Conditions
Healthy
Interventions
BIOLOGICAL

IL-YANG FLU Vaccine Prefilled Syringe INJ.

IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL

BIOLOGICAL

VAXIGRIP Prefilled Syringe INJ.

VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL

All Listed Sponsors
lead

Il-Yang Pharm. Co., Ltd.

INDUSTRY

NCT02263131 - Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children | Biotech Hunter | Biotech Hunter